Pharmacological treatments aim for targeted and precision therapy in many difficult-to-treat and chronic diseases. Innovation needs multi-centre, controlled at the level of Phase I to III trials to evaluate risk and benefits for patients. These innovations are urgently needed for patients with treatment failure with standard treatment.
The clincal study centre conducts clincial trials with a focus on lung cancer, but also in the field of interstitial lung diseases, COPD and HIV. The study team collects and provides data for the analysis of safety, efficacy, tolerability and also rentability of novel therapies. These results may support the approval at health authorities. Once these novel therapies become standard of care, a large patient population an benefit from them.
